Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Enrolling By Invitation
18 years - 99 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The research study is being conducted to study the effectiveness of the mRNA-1273 study vaccine in people who have received a kidney or liver transplant. Healthy participants are being included in the study to compare the results from these participants to those who have had a kidney or liver transplant.
Participants will be asked to complete the following research procedures:
• Study vaccination
• Electronic diary completion for symptom screening
• Blood and urine collection
• Nasopharyngeal swab collection
Participation will last for approximately 13-15 months.
The research study is sponsored by ModernaTX, Inc. (ModernaTX). ModernaTX, is studying the mRNA-1273 vaccine for the prevention of COVID-19 in participants who have some types of solid organ transplant
Compensation of up to is available $1770.00 to complete the study. Compensation will be provided based on a visit- completion schedule.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: transplant,mRNA
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 849547
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
